Last reviewed · How we verify

NCT00001638

Magnetic Resonance Imaging of the Blood Vessels of the Heart

Completed Last updated 4 August 2022
What this trial tests

trial in Heart Disease in 2,916 participants. Completed in 3 August 2009.

Timeline
29 September 1997
Primary endpoint
3 August 2009
3 August 2009

Quick facts

Lead sponsorNational Heart, Lung, and Blood Institute (NHLBI)
StatusCompleted
Study typeOBSERVATIONAL
Enrollment2,916
Start date29 September 1997
Primary completion3 August 2009
Estimated completion3 August 2009
Sites2 locations across United States

Conditions studied

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Who can join

18 and older, any sex, with Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is directed at evaluating patients with "myocardial ischemia" or poor blood supply to the heart muscle due to coronary artery disease. The major objective of this study is to determine the level of safety and effectiveness of magnetic resonance imaging at diagnosing coronary artery disease. In addition, this study will allow researchers at the National Institutes of Health to see a broad spectrum of disease, preserve clinical skills, and stimulate future ideas for clinical research....

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Heart Disease

Currently open trials in the same condition.

Other National Heart, Lung, and Blood Institute (NHLBI) trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00001638.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing